Strategic Regulatory and IP Considerations for Emerging Life Sciences Companies in the US and Canada 
Featuring updates on the Regulatory and IP requirements for North America

Thursday January 28th 2.00pm (Atlantic time) 

Key Takeaways
- Determining whether and how you are regulated by FDA or Health Canada
- Choosing a regulatory pathway to market
- Developing data to support marketing authorization (such as INDs, IDEs, human factors studies, consumer preference testing)
- Understanding the strategic and compliant use of experts and key opinion leaders (including Sunshine and conflicts of interest considerations)
- Identifying critical considerations that shape a strategic patent portfolio regarding such issues as market exclusivity, protection from copycats and enforceability of patent claims
- Developing a communication strategy for products in development and on the market

Hosted by DLA Piper www.dlapiper.com - a global law firm with an active life science portfolio, and is keen to work with emerging life science SMEs at affordable rates. If you are interested in connecting with DLA Piper in your region, please contact Sara Zborovski, This email address is being protected from spambots. You need JavaScript enabled to view it.

For more info or to register click here 





Wednesday the 23rd. © 2018. All rights reserved.. Bridgewater Media Services